Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07627074 · ClinicalTrials.gov registry record
Weight Loss in Adults Using Semaglutide (Real-world Study)
A clinical trial, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- 35,000
- Enrollment target
NCT07627074: Recruiting study, sponsored by Novo Nordisk A/S.
NCT07627074 is a clinical trial that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 35,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07627074 is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- 35,000 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Primary Outcome
Measured as kilogram (kg)
Interventions
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,000 participants |
| Start Date | 2026-05-12 |
| Est. Completion | 2026-06-01 |
What NCT07627074 shows while recruiting
NCT07627074 is an observational study that tracks outcomes without assigning an intervention. Its 35,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Semaglutide is the first listed.
NCT07627074 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07627074 about?
NCT07627074 is a clinical study titled "Weight Loss in Adults Using Semaglutide (Real-world Study)". The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
What is the current status of trial NCT07627074?
This trial is currently recruiting. The enrollment target is 35,000 participants. The study started on 2026-05-12. Estimated completion is 2026-06-01.
What interventions are being tested in trial NCT07627074?
The interventions under investigation include: Semaglutide (DRUG).
Who is sponsoring clinical trial NCT07627074?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI